X

Trial Profile

A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neoadjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabazitaxel (Primary) ; Cisplatin
Indications Bladder cancer; Carcinoma
Focus Therapeutic Use
Acronyms Bristol Bladder Trial

Most Recent Events

18 Feb 2023 Results of Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder, at the 2023 Genitourinary Cancers Symposium
11 Nov 2020 Planned End Date changed from 1 Jan 2018 to 1 Jan 2023.
11 Nov 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com